Market Research Logo

Cedar Pollen Allergy - Pipeline Review, H2 2016

Cedar Pollen Allergy - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Cedar Pollen Allergy - Pipeline Review, H2 2016’, provides an overview of the Cedar Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy
    • The report reviews pipeline therapeutics for Cedar Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Cedar Pollen Allergy therapeutics and enlists all their major and minor projects
    • The report assesses Cedar Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Cedar Pollen Allergy Overview
    Therapeutics Development
    Pipeline Products for Cedar Pollen Allergy - Overview
    Pipeline Products for Cedar Pollen Allergy - Comparative Analysis
    Cedar Pollen Allergy - Therapeutics under Development by Companies
    Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes
    Cedar Pollen Allergy - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Cedar Pollen Allergy - Products under Development by Companies
    Cedar Pollen Allergy - Products under Investigation by Universities/Institutes
    Cedar Pollen Allergy - Companies Involved in Therapeutics Development
    ALK-Abello A/S
    Astellas Pharma Inc.
    Circassia Pharmaceuticals Plc
    Immunomic Therapeutics, Inc.
    Japan Tobacco Inc.
    REGiMMUNE Corporation
    Cedar Pollen Allergy - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ASP-4070 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biologic for Cedar Pollen Allergy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JCC-LAMP-Vax - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RGI-1001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TO-206 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Cedar Pollen Allergy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Japanese Cedar Pollen Allergy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cedar Pollen Allergy - Dormant Projects
    Cedar Pollen Allergy - Product Development Milestones
    Featured News & Press Releases
    Aug 07, 2015: ALK’s partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet
    Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference
    Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting
    Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy
    Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Cedar Pollen Allergy, H2 2016
    Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Cedar Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2016
    Cedar Pollen Allergy - Pipeline by Astellas Pharma Inc., H2 2016
    Cedar Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
    Cedar Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2016
    Cedar Pollen Allergy - Pipeline by Japan Tobacco Inc., H2 2016
    Cedar Pollen Allergy - Pipeline by REGiMMUNE Corporation, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Cedar Pollen Allergy - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Cedar Pollen Allergy, H2 2016
    Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report